Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research on the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation E. Intensify research on the major drivers of childhood cancers: Improve our understanding of fusion oncoproteins in pediatric cancer and use new preclinical models to develop inhibitors that target them. The goal of this FOA is to establish a consortium of collaborating research teams to advance our understanding of the biology and mechanisms of action of fusion oncoproteins in pediatric cancers, and to apply this knowledge towards developing targeted therapeutic approaches. Increased attention to this important but understudied field can help overcome existing barriers to progress and pave the way to novel therapeutic approaches with increased efficacy and fewer side effects for patients than current options. The research teams comprising the Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium will take a comprehensive approach to understanding the biology of fusion oncoproteins in childhood cancers and will use this information to inform strategies for therapeutic targeting. Each U54 Center should include three to four related research projects that are focused on a specific fusion oncoprotein.


  • Letter of Intent Due Date(s): November 7, 2018
  • Application Due Date(s): December 7, 2018

RFA-CA-19-016 Expiration Date December 8, 2018

Agency Website



Amount Description

Center budgets are limited to $1.6 million direct costs per year, and need to reflect the actual needs of the proposed projects and activities.

The scope of the proposed activities should determine the project period for the Center. The maximum project period is 5 years.

    Funding Type





    Engineering and Physical Sciences
    Environmental & Life Sciences
    Medical - Basic Science
    Medical - Clinical Science
    Medical - Translational

    External Deadline

    December 7, 2018